



NOTHING SECURES LIKE MASTISOL®

“Locks down” catheter dressings to help adhere to CDC guidelines



mastisol[®]
LIQUID ADHESIVE

ENSURE COMPLIANCE WITH CDC GUIDELINES

Subclavian central line catheter dressing



DATA POINT

In a clinical study, 6 times the number of patient dressings secured with Mastisol remained intact compared to dressings secured with benzoin.⁴

Foley catheter securement device



Protect against the risk of infection

CDC Guidelines for the Prevention of Intravascular Catheter-Related Infections recommend:

- Replacement of catheter site dressing if damp, loosened, or visibly soiled (Category IB)¹
- Replacement of dressings on short-term central venous catheter (CVC) sites at least every 7 days (Category IB)¹

CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections recommend:

- Properly secured indwelling catheters after insertion to prevent movement and urethral traction (Category IB)²

Assure adherence



- Mastisol is a nonwater soluble adhesive
 - Ensures that dressings will remain intact if the patient is diaphoretic or if the dressings are placed in moist, contaminant prone areas
- More than 8 million applications every year³
- Adhesion is superior to tincture of benzoin⁴

Improve the level of security

Reduce the risk of infection

- Recent data suggests that dressing disruptions are a major risk factor for catheter-related infections⁵
- In a study of catheter-related bloodstream infections: 60% of infections were attributed to skin flora or other contamination coming in contact with the catheter insertion point⁶
- Mastisol minimizes infection risk by helping to keep the system closed and the dressing intact for the recommended dressing stay time

Enhance tape/dressing performance

- In a study designed to evaluate the effects of different techniques used to secure intravenous catheters: Pretreatment of skin with Mastisol enhanced the adhesive performance of all tapes tested,* better than benzoin or no treatment at all⁷
- Mastisol can also enhance the adhesive performance of a variety of occlusive dressings and devices

DATA POINT

A study showed that contact dermatitis developed in 38% (57/150) of benzoin-treated patients compared with 0.7% (1/150) of Mastisol-treated patients.⁴

SECURE BENEFITS FOR PATIENTS AND CLINICIANS ALIKE

Range of sizes and sterile unit-of-use vials provide:

- Efficiency
- Value
- Standardization

- Mastisol can improve patient safety
 - Minimizes the risk of infection by creating a lasting occlusive dressing barrier, particularly around CVC sites
 - Reduces the likelihood of dressing displacement and device dislodgement
 - Reduced risk of adverse reactions (lower incidence of postoperative contact dermatitis and skin discoloration than tincture of benzoin)⁴
 - Is latex free to alleviate potential allergic reactions
- Mastisol assures convenience and versatility for healthcare professionals
 - Long-lasting adhesion saves time and cost of multiple dressing replacements or device dislodgements
 - Versatility across a range of procedures and applications

mastisol
LIQUID ADHESIVE



Peripheral IV catheter dressing



*Maximum force (Newtons) to dislodge IV catheters using Transpore (plastic), Curity (cloth), and Leukopor (silk) tape alone, and with Mastisol and benzoin skin pretreatment.

MASTISOL SUPPORTS YOUR INITIATIVES TO MEET CDC RECOMMENDATIONS



CDC GUIDELINES

For prevention of intravascular catheter-related infections (Category IB)¹
For prevention of catheter-associated urinary tract infections (Category IB)²

- Mastisol improves patient safety by
 - Minimizing the risk of infection by reinforcing the dressing barrier
 - Reducing the chance of device dislodgement and dressing displacement
 - Helping to secure dressings even in moist areas
- Mastisol assures convenience and versatility for healthcare professionals
 - Long-lasting adhesion saves time and cost of multiple dressing replacements or device dislodgements
 - Versatility across a range of procedures and applications
 - Range of sizes including sterile unit-of-use vials

ORDERING INFORMATION

DESCRIPTION	UNIT	HRI#
Mastisol Vials	48 X 2/3mL	0496-0523-48
Mastisol Unit Dose	15mL bottle with plug	0496-0523-15
Mastisol Spray	15mL bottle with spray	0496-0523-16
Mastisol Dispenser Cap	2oz bottle	0496-0523-06



For more information, please contact your sales consultant or Eloquest Healthcare® toll free: 1-877-433-7626, or on the web: www.mastisol.com



Mastisol is an essential product in the Eloquest Healthcare® portfolio.



mastisol
LIQUID ADHESIVE

Procedures & Applications

- Central line dressings
- Foley catheter securement
- Peripheral IV dressings
- ET tube securement
- NG tube securement
- Wound closure strips
- V.A.C.® Therapy Dressings

Additional beneficial products include: Detachol® Adhesive Remover and L.M.X.4® Topical Anesthetic Cream

References: 1. Guidelines for the prevention of intravascular catheter-related infections. 2011. Centers for Disease Control website. <http://www.cdc.gov/hicpac/pdf/guidelines/bsi-guidelines-2011.pdf>. Accessed January 29, 2013. 2. Guidelines for the prevention of catheter-associated urinary tract infections. 2009. Centers for Disease Control website. <http://www.cdc.gov/hicpac/pdf/CAUTI/CAUTIguideline2009final.pdf>. Accessed January 29, 2013. 3. GHX Market Data, Liquid Adhesives Class 10-036, 2012. 4. Lesesne CB. The postoperative use of wound adhesives: gum mastic versus benzoin. *USP J Dermatol Surg Onc.* 1992;18(1):990. 5. Timsit J, et al. Dressing disruption is a major risk factor for catheter-related infections. *Crit Care Med.* 2012;40(6):1707-1714. 6. Safdar N, Maki DG. The pathogenesis of catheter-related bloodstream infections with noncuffed short-term central venous catheters. *Int Care Med.* 2004; 30:62-67. 7. Patel N. The influence of tape type and of skin preparation on the force required to dislodge angiocatheters. *Can J Anaesth.* 1994;41:8:738-741.

Mastisol, Eloquest Healthcare, Detachol, Microcyn Rx Solution, and L.M.X.4 are registered trademarks of Ferndale IP, Inc.

V.A.C.® is a registered trademark of KCI Licensing, Inc.

© 2013 Eloquest Healthcare®, Inc. MA40 3/13